Incretin-based Drugs and the Risk of Heart Failure: A Multi-center Network Observational Study
This multi-center observational study investigates the association between incretin-based drugs and the risk of heart failure (HF) in patients with type 2 diabetes. Given the increasing prevalence of diabetes and the significant market for anti-diabetic medications, understanding the cardiovascular safety profile of incretin-based therapies is critical for market positioning. The results may influence prescribing practices and regulatory scrutiny, potentially impacting the competitive landscape among diabetes treatments. Companies involved in the development of incretin-based therapies may need to reassess their risk management strategies and market communications based on the findings of this study.
Indication: Type 2 Diabetes Mellitus
Modality: small molecule
Target: Incretin receptors (GLP-1 and GIP receptors)
Sponsor: Canadian Network for Observational Drug Effect Studies, CNODES
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jun 25, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Incretin receptors (GLP-1 and GIP receptors)
View original source fields
Condition raw: Type 2 Diabetes Mellitus
Condition normalized: Type 2 Diabetes Mellitus
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Incretin receptors (GLP-1 and GIP receptors)
Target normalized: Incretin receptors (GLP-1 and GIP receptors)